CN
CN
Establishing a Solid Future for 3SBio through Transparent Management |
The 3SBio’s governance philosophy stems from our company mission - to make the greatest value for patients, customers, colleagues, investors, business partners and society.
Below please find the biography of Directors, overview of the Board committees, and corporate governance documents.
The board of directors includes nine directors, of which four are executive directors, two non-executive directors and three are independent non-executive directors.
Responsible for Group strategic development and planning, overall operation management and major decision-making
Dr. LOU Jing, was appointed as a Director on 5 September 2006 and was redesignated as an executive Director on 27 November 2014. He was appointed as the chairman of the Board on 1 April 2012. Dr. Lou is also the chief executive officer of the Company. He is responsible for the strategic development and planning, overall operational management and major decision making of the Group. He is a co-founder of the Group and joined Shenyang Sunshine Pharmaceutical Company Limited (“Shenyang Sunshine”) as a director of R&D in September 1995.
Dr. Lou also holds the following positions with other members of the Group:
1) director and chairman of the board of Collected Mind Limited (集思有限公司, “Collected Mind”);
2) director of Hongkong Sansheng;
3) director of Excel Partner Holdings Limited (特隆控股有限公司, “Excel Partner”);
4) director of Ample Harvest Investments Limited (溢丰投资有限公司, “Ample Harvest”);
5) director, chief executive officer and president of Shenyang Sunshine and chairman of the board of Shenyang Sunshine;
6) director and chairman of the board of Taizhou Huan Sheng Investment Management Company Limited (泰州环晟投资管理有限公司, “Taizhou Huan Sheng Investment”);
7) executive director of Shenzhen Baishitong Technology Development Company Limited (深圳市百士通科技开发有限公司, “Shenzhen Baishitong”);
8) chairman of the board of Shenzhen Sciprogen Bio-pharmaceutical Co., Ltd. (“Sciprogen”);
9) chairman of the board of Guangdong Sunshine Pharmaceutical Co., Ltd. (广东三生制药有限公司);
10) director and chairman of the board of NMV Desen Biotech Co., Ltd;
11) director of Gains Prestige Limited (泽威有限公司, “Gains Prestige”);
12) director of Strategic International Group Limited (“Strategic International”);
13) director and chairman of the board of Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (“Sunshine Guojian”);
14) director and chairman of the board of Shanghai Xingsheng Pharmaceutical Company Limited (“Xing Sheng”);
15) executive director of Shanghai An Ran Biotech Co. Ltd.;
16) executive director of Sunshine Guojian Pharmaceuticals (Suzhou) Co. Ltd.;
17) director of Full Gain Pharmaceutical Limited;
18) director of Shanghai National Engineering Research Center of Antibody Medicine Co. Ltd.;
10) chairman of the board of Xinyisheng (Hainan) Commercial Factoring Co., Ltd.;
20) director of 3SBio (Hongkong) Limited;
Dr. Lou has been highly active in pharmaceutical research and has made substantial contribution to the Group’s R&D of pharmaceutical products. Dr. Lou was the leading scientist and principal investigator in the Group’s successful development of EPIAO and TPIAO. He co-invented a “preparation process for recombinant human thrombopoietin” and a “method for improving the stability of polypeptides in human bodies and its application” in 2000 and 2001, respectively. He has published in a number of academic journals on microbiology and medicinal biotechnology. His research has been recognized with various awards. In 2006, he was awarded the “First Prize of Shenyang Science and Technology Progress Award” (沈阳市科学技术进步一等奖) for his research on recombinant human thrombopoietin. In 2007, he was awarded the “Third Prize of Liaoning Province Scientific and Technological Achievements” (辽宁省科学成果转化三等奖) for his contribution to the industrialization of production of recombinant human thrombopoietin. In 2017, he was awarded “Liaoning Province Outstanding Entrepreneur” and “Friendship Award of Liaoning Province”. In 2022, he received the 15th “Tan Jia Zhen Life Sciences Award” . Dr. Lou obtained a Bachelor of Medicine degree in clinical medicine from Shanghai Second Military Medical University in July 1985. He conducted post-doctoral research at the National Institutes of Health of the United States after obtaining a Ph.D. degree in molecular and cell biology from Fordham University in the United States in February 1994. He also obtained an Executive Master of Business Administration from China Europe International Business School (中欧国际工商学院) in September 2008.
Ms. SU Dongmei was appointed as a Director on 11 June 2012 and was re-designated as an executive Director on 27 November 2014. Ms. Su is also the Company’s senior vice president and the general manager of Shenyang Sunshine. She is responsible for strategic direction of the Group. Ms. Su joined Shenyang Sunshine as a scientist of the research and development department in January 1993, and served as a director of the R&D department from 1997 to 2006. She subsequently served as the chief technology officer responsible for R&D and manufacturing process engineering of Shenyang Sunshine from 2006 to 2008. Ms. Su was promoted to vice president of Shenyang Sunshine in April 2008. Ms. Su served as a director of Shenyang Sunshine from August 2007 to June 2013, and was re-appointed on 18 July 2016. She also served as a director of Hongkong Sansheng from November 2009 to November 2014.
Ms. Su also holds the following positions with other members of the Group: (i) senior vice president of Shenyang Sunshine; (ii) supervisor of Liaoning Sunshine; (iii) director of Sciprogen; (iv) director of Guangdong Sunshine; (v) director of Strategic International; (vi)executive director of Shenyang Jiasheng Agriculture Technology Co., Ltd.; (vii) director of Sunshine Guojian; (viii) executive director of Shanghai Bo Ai Ke Biotech Co. Ltd.; (ix) trustee of Shanghai Sunshine Guojian Biotech Research Institute; (x) Director of Northern Medicine Valley Desen (Shenyang) Biologics Co., Ltd.
Ms. Su obtained a Bachelor’s degree in Biochemistry from Jilin University (吉林大學) in July 1992 and a Master’s and a Doctorate degree in Microbiology and Pharmacology from Shenyang Pharmaceutical University (瀋陽藥科大學) in June 2001 and July 2010, respectively. She has published in a number of academic journals on microbiology and medicinal biotechnology.
Ms. ZHANG Jiao’e was appointed as a non-executive Director on 25 June 2024.
Ms. ZHANG has extensive experience in the field of medicine and pharmaceuticals. She worked as a research assistant in the Military Medical Research Institute of the Logistics Department of the Shenyang Military Region (瀋陽軍區後勤部軍事醫學研究所 ) from August 1987 to December 1990. In January 1993, Ms. ZHANG joined Shenyang Sunshine Pharmaceutical Co., Ltd. (瀋陽三生製藥有限責任公司) and has held various positions within the Group ever since. She served as a manager at Shenyang Sunshine from July 1993 to December 2001 and was appointed as the deputy factory director and head of the foreign cooperation department in January 2002 and May 2011, respectively. In March 2016, Ms. ZHANG became the assistant to the general manager of Shenyang Sunshine. She currently serves as the general manager of Liaoning Sunshine Technology Development Co., Ltd. (遼寧三生科技發展有限公司). Currently, she is also a supervisor of each of Northern Medicine Valley Desen (Shenyang) Biologics Co., Ltd. (北方藥谷德生（瀋陽）生物科技有限責任公司) and Zhejiang Sunshine Mandi Pharmaceutical Co., Ltd. (浙江三生蔓迪藥業有限公司).
Ms. ZHANG obtained a bachelor’s degree from the China Pharmaceutical University (中國藥科大學) in July 1987 and earned her qualifications as a chief pharmacist from the Human Resources Security Department of Liaoning Province (遼寧省人力資源和社會保障廳) in September 2010.
Mr. PU Tianruo was appointed as an independent non-executive Director on 23 May 2015, with such appointment taking effect on 1 June 2015. Previously, he served as an independent Director and the audit committee chair of the Company from 1 September 2012 to 29 May 2013.
Mr. Pu has substantial experience in accounting and finance. He serves as an independent non-executive director of several companies, including Autohome Inc. (NYSE: ATHM; HKEx stock code: 2518) since December 2016 and One Connect Financial Technology (NYSE: OCFT; HKEx stock code: 6638) since December 2019. He has also served as an independent non-executive director of AnPac Bio-Medical Science Co., Ltd. (formerly Nasdaq: FRES) since October 2022. He was previously the chief financial officer of Zhaopin Ltd. (previously NYSE: ZPIN). Mr. Pu obtained a Bachelor’s degree in English Language from China Foreign Affairs University (外交學院) in July 1991, a Master of Science degree in Accounting from the University of Illinois, College of Business Administration in May 1996 and an MBA degree from Northwestern University Kellogg School of Management in the U.S. in June 2000.
Ms. YANG, Hoi Ti Heidi ( 楊 凱 蒂 ) was appointed as an independent non-executive Director on 29 June 2021. Ms. YANG has been the Global Managing Director, Asian and World Art at Christie’s Hong Kong Limited since January 2021 and had served as a member of the Listing Committee of the Stock Exchange from July 2019 to July 2021. Prior to joining Christie’s Hong Kong Limited, Ms. YANG had over 28 years of experience in the financial sector and had held the positions of Managing Director and Head of Corporate Advisory Group, Asia Pacific at Deutsche Bank Asia Limited, Managing Director and Head of Corporate Finance Group at UBS Investment Bank Asia, and Analyst, Associate and Vice President at Morgan Stanley Asia Limited. Ms. YANG holds a Bachelor of Arts degree majoring in economics from Columbia University, New York.
Mr. NG, Joo Yeow Gerry (黃祖耀) was appointed as an independent non-executive Director on 21 January 2022. He has substantial experience in corporate planning, business expansion and development as well as cross-border management, particular in the investment management business in the Asian region. Mr. Ng has been an Independent Non-executive Director of AIA Company (Trustee) Limited, a subsidiary of AIA Group Limited (HK Stock Code: 1299), since August 2021, for its pension fund business in Hong Kong. He had served as the Chief Executive Officer, Asia ex Japan of Baring Asset Management (Asia) Limited (“Baring Asset Management”) up to December 2019, having been appointed as Managing Director of Baring Asset Management in December 2004. During his time at Baring Asset Management, Mr. Ng managed and had oversight of different offices in the Asian region including those in Shanghai, Hong Kong, Taipei and Seoul, and was responsible for the business management of a substantial book of business in retail mutual funds and institutional client assets. Mr. Ng has also had ample and broad range of experience working with key sovereign wealth funds, large institutions and regulators in the region. Prior to joining Baring Asset Management, Mr. Ng was employed by JF Asset Management Limited (now JP Morgan Asset Management (Asia Pacific) Limited) from May 1992 to November 2004. During this period, he held various positions including Head of Asian Institutional Clients and Finance Director (JF Unit Trusts), and had focused on sales, business development and client servicing in the Asian region. Mr. Ng had also worked at Price Waterhouse (now PricewaterhouseCoopers) in both London and Hong Kong from September 1986 to April 1992 with his last role serving as an Audit Manager in the Hong Kong office.
Mr. Ng is a Senior Fellow of the Hong Kong Securities and Investment Institute and has also previously held many respectable and prestigious positions in different professional and regulatory bodies, including formerly being a Member of the Securities and Futures Appeals Tribunal, the Chairman and Executive Committee Member of Hong Kong Investment Funds Association, a Panel Member of the Mandatory Provident Fund Schemes Appeal Board, and a Member of Hong Kong Trade Development Council Financial Services Advisory Committee.
Mr. Ng holds a Bachelor of Science degree (with first class honours) majoring in civil engineering from Imperial College, London. He is also a Chartered Accountant (England and Wales) and Certified Public Accountant (Hong Kong).
We have established a Audit Committee in accordance with the Corporate Governance Code contained in Article 3.21 of Listing Rules and Appendix 14 of Listing Rules. The main responsibilities of the Audit Committee are to review and supervise the Company's financial reporting process and internal control system, review and approve connected transactions and provide advice to the Board. The Audit Committee currently comprises three members, including a non-executive director, namely Mr. HUANG Bin, and two independent non-executive Directors, namely, Mr. PU Tianruo (Chairman) and Dr. WONG Lap Yan. The chairman of the committee, Mr. Pu Tianruo, holds the appropriate qualifications as stipulated in Articles 3.10(2) and 3.21 of Listing Rules.
We have established a Remuneration Committee in accordance with the Corporate Governance Code contained in Article 3.25 of Listing Rules and Appendix 14 of Listing Rules. The main responsibilities of the Remuneration Committee are to review the terms of compensation plans, bonuses and other compensation payable to directors and senior management and make recommendations to the board in this regard. The Remuneration Committee currently comprises three members, including two independent non-executive Directors, namely Dr. WONG Lap Yan (Chairman) and Mr. PU Tianruo, and a non-executive Director, namely Mr. TANG Ke.
We have established a Nominations Committee in accordance with the Corporate Governance Code contained in Appendix 14 of Listing Rules. The main responsibilities of the Nominations Committee are to make recommendations to the Board on the appointment of directors and the succession of the board of directors. The Nomination Committee currently comprises three members, including an executive Director, Dr. LOU Jing (Chairman), and two independent non-executive Directors, namely, Mr. PU Tianruo and Dr. WONG Lap Yan.